My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.190 -0.050 (-4.03%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Ocugen (OCGN) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Ocugen (OCGN) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

OCUGEN INC (NASDAQ:OCGN) Reports Mixed Q3 2025 Results Amid Clinical Pipeline Progress ↗

November 05, 2025

Ocugen reports Q3 2025 results with a major revenue beat and updates on its late-stage gene therapy pipeline for blindness diseases.

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Forecasting The Future: 4 Analyst Projections For Ocugen ↗

September 19, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 17, 2025

Via Benzinga

Why Ocugen Stock Zoomed 12% Higher Today ↗

September 15, 2025

A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs.

Via The Motley Fool

Demystifying Ocugen: Insights From 5 Analyst Reviews ↗

August 04, 2025

Via Benzinga

A Peek at Ocugen's Future Earnings ↗

July 31, 2025

Via Benzinga

Ocugen Shares Are Trading Higher Monday: What's Going On? ↗

September 15, 2025

Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.

Via Benzinga

Ocugen (OCGN) Q2 Revenue Jumps 20% ↗

August 01, 2025

Via The Motley Fool

Ocugen Inc (NASDAQ:OCGN) Q2 2025 Earnings: Revenue Surges, EPS Loss Narrows ↗

August 01, 2025

Ocugen Inc (OCGN) reports Q2 2025 earnings with $1.37M revenue, beating estimates by 284%, while EPS loss narrows to -$0.05. Progress in gene therapy trials boosts investor optimism.

Via Chartmill

5 Biotech Stocks with Highly Anticipated Pending Results ↗

June 26, 2025

Via Stocktwits

Topics Intellectual Property

Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On? ↗

June 23, 2025

Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics.

Via Benzinga

A Look at Ocugen's Upcoming Earnings Report ↗

May 08, 2025

Via Benzinga

Beyond The Numbers: 5 Analysts Discuss Ocugen Stock ↗

March 06, 2025

Via Benzinga

Expert Outlook: Ocugen Through The Eyes Of 4 Analysts ↗

February 13, 2025

Via Benzinga

Earnings Scheduled For August 1, 2025 ↗

August 01, 2025

Via Benzinga

Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial ↗

June 16, 2025

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients who currently have no other options.

Via Benzinga

Navigating 4 Analyst Ratings For Ocugen ↗

November 11, 2024

Via Benzinga

A Preview Of Ocugen's Earnings ↗

November 07, 2024

Via Benzinga

Peering Into Ocugen's Recent Short Interest ↗

August 09, 2024

Via Benzinga

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday ↗

May 12, 2025

Via Benzinga

The Analyst Verdict: Ocugen In The Eyes Of 5 Experts ↗

May 12, 2025

Via Benzinga

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish ↗

May 09, 2025

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three...

Via Stocktwits

Topics Lawsuit

Earnings Scheduled For May 9, 2025 ↗

May 09, 2025

Via Benzinga

Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates ↗

March 05, 2025

Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years.

Via Stocktwits

Ocugen (OCGN) Q4 2024 Earnings Call Transcript ↗

March 05, 2025

OCGN earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Earnings Scheduled For March 5, 2025 ↗

March 05, 2025

Via Benzinga

Ocugen (OCGN) Q3 2024 Earnings Call Transcript ↗

November 08, 2024

OCGN earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Ocugen (OCGN) Q2 2024 Earnings Call Transcript ↗

August 08, 2024

OCGN earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.